Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results - Meric-Bernstam, F; Makker, V; Oaknin, A (J Clin Oncol, 2023)
et al.